BI 1815368
Alternative Names: BI-1815368Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 23 Oct 2024 Boehringer Ingelheim plans a phase I drug-drug interaction trial (In volunteers) in Germany in November 2024 (PO) (NCT06655220) (EUCT2024-515911-23-00)
- 10 Jul 2024 Boehringer Ingelheim plans a phase I trial (In volunteers) (PO), in August 2024 (NCT06494774, 1485-0005)
- 02 Aug 2023 Boehringer Ingelheim plans a phase I trial (In volunteers) in unknown location (PO) (NCT05965583)